A5027833091- Asthma and respiratory diseases
- Angiogenesis and VEGF in Cancer
- Allergic Rhinitis and Sensitization
- IL-33, ST2, and ILC Pathways
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Nonmelanoma Skin Cancer Studies
- Immunotherapy and Immune Responses
- SARS-CoV-2 and COVID-19 Research
- Ovarian cancer diagnosis and treatment
- Dermatology and Skin Diseases
- Cell Adhesion Molecules Research
- Pancreatic and Hepatic Oncology Research
- COVID-19 Clinical Research Studies
- Hedgehog Signaling Pathway Studies
- Respiratory and Cough-Related Research
- Eosinophilic Esophagitis
- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Complement system in diseases
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Respiratory viral infections research
Regeneron (United States)
2019-2023
Memorial Hospital
2022
Pontifícia Universidade Católica do Rio Grande do Sul
2022
Harvard University
2021
Brigham and Women's Hospital
2021
University of Oxford
2021
Arizona Liver Health
2020
Amgen (United States)
2010-2012
Genex Systems (United States)
2006
National Cancer Institute
2002-2006
BackgroundRecent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads.MethodsIn this ongoing, double-blind, phase 1–3 trial involving nonhospitalized patients with Covid-19, we investigated two fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome 2 (SARS-CoV-2) spike protein, used in a combined cocktail (REGN-COV2) reduce the risk of emergence treatment-resistant mutant virus. Patients were...
Colloidal gold, a sol comprised of nanoparticles Au0, has been used as therapeutic for the treatment cancer well an indicator immunodiagnostics. However, use these gold in vivo drug delivery never described. This communication outlines development colloidal (cAu) nanoparticle vector that targets tumor necrosis factor (TNF) to solid growing mice.The optimal vector, designated PT-cAu-TNF, consists molecules thiol-derivatized PEG (PT) and recombinant human TNF are directly bound onto surface...
Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder associated with genetic variants that result in virtually absent (null–null) or impaired (non-null) LDL-receptor activity. Loss-of-function the gene encoding angiopoietin-like 3 (ANGPTL3) are hypolipidemia and protection against atherosclerotic disease. Evinacumab, a monoclonal antibody ANGPTL3, has shown...
Children with severe atopic dermatitis (AD) have limited treatment options.We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years AD inadequately controlled therapies.In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1 to 300 mg every 4 weeks (300 q4w), a weight-based regimen 2 (100 q2w, baseline weight <30 kg; 200 ≥30 kg), or placebo; concomitant medium-potency TCS.Both q4w q2w TCS regimens...
Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)–blocking antibody approved to treat lung and skin cancers, has been shown preliminary clinical activity in this population.
Monoclonal antibodies targeting IgE, interleukin-4 and -13, interleukin-5 are effective in treating severe type 2 asthma, but new targets needed. Itepekimab is a monoclonal antibody against the upstream alarmin interleukin-33. The efficacy safety of itepekimab as monotherapy, well combination with dupilumab, patients asthma unclear.In phase trial, we randomly assigned, 1:1:1:1 ratio, adults moderate-to-severe receiving inhaled glucocorticoids plus long-acting beta-agonists (LABAs) to receive...
Abstract First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free (PFS) versus chemotherapy patients with advanced non-small lung cancer (aNSCLC) PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase study, examined plus platinum-doublet as first-line treatment for aNSCLC, irrespective of PD-L1 or histology. In this 466 stage...
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults PN ≥20 nodules severe itch uncontrolled topical therapies. Dupilumab, fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 IL-13. Patients were randomized 1:1 to 300 mg dupilumab or placebo subcutaneously every 2 weeks 24 weeks. primary endpoint was pruritus improvement, measured by proportion of...
Abstract BACKGROUND: Interleukin 1 (IL-1) is a pluripotent cytokine that promotes angiogenesis, tumor growth, and metastasis in experimental models; its presence some human cancers associated with aggressive biology. The purpose of these studies was to characterize the role IL-1 determine if inhibition via receptor antagonist, IL-1Ra, alters growth metastatic potential. METHODS: mRNA or protein levels were determined clinical samples, cancer cell lines, xenografts using quantitative reverse...
To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes interaction between Tie2 receptor angiopoietin-1/2, plus weekly paclitaxel in patients with recurrent ovarian cancer.Patients epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned 1:1:1 to receive (80 mg/m(2) once [QW], 3 weeks on/1 week off) intravenous 386 10 mg/kg QW (arm A), B), placebo C). The end point was progression-free survival (PFS)....
Respiratory syncytial virus (RSV) is a major cause of childhood medically attended respiratory infection (MARI).
Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for treatment adults and adolescents as well other type 2 inflammatory diseases.
The efficacy of an allergen-specific IgG cocktail to treat cat allergy suggests that may be a major protective mechanism elicited by allergen immunotherapy.Extending these findings, we tested Bet v 1-specific antibody in birch-allergic subjects.This was phase 1, randomized, double-blind, study with 2 parts. Part A administered ascending doses the REGN5713/14/15 (150-900 mg) 32 healthy adults. B single subcutaneous 900-mg dose or placebo 64 subjects. Total nasal symptom score response...
Abstract IL-1β is a pleotropic cytokine that may mediate increased procoagulant activity and permeability in endothelial tissue during inflammatory conditions. The effects of are mediated through induction factor (TF) but its alterations on vascular not well characterized. We found induced rapid dose-dependent increase TF human umbilical vein cells (ECs) under routine culture However, caused marked across confluent EC monolayers using two-compartment vitro model only the presence...
Objective The development of biomarkers to guide treatment decisions is a major research focus in rheumatoid arthritis ( RA ). Patients with have elevated interleukin‐6 IL ‐6) levels; however, the utility ‐6 as predictor response unclear. This study was undertaken investigate, by post hoc analysis, whether baseline levels are predictive sarilumab responses 2 phase III studies. Methods Serum concentrations were measured patients prior receiving 200 mg (n = 148) or adalimumab 40 152) every...
ABSTRACT Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; REGEN-COV, retains activity vitro against emerging SARS-CoV-2 variants concern. Methods The 3 adaptive, randomized, master protocol, included 4,057 Covid-19 outpatients one or more risk factors for severe disease. Patients were randomized to a single treatment intravenous placebo, various doses followed 28...
BackgroundThe dominant allergen in cat dander, Felis domesticus 1 (Fel d 1), is a persistent trigger for allergic rhinitis and asthma symptoms.ObjectiveWe evaluated the efficacy of Fel monoclonal antibodies (REGN1908/1909) preventing allergen–induced early asthmatic responses (EARs) cat-allergic patients with mild asthma.MethodsPatients were randomized to single-dose REGN1908/1909 600 mg (n = 29) or placebo 27). The FEV1 was measured up 4 hours environmental exposure unit 85 days after...